http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021252895-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd3166684d58c1e207a8f43f761dbbe3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4704 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate | 2021-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b61f42580a5d161538d046c43f2b60a0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89593236ce731dd982f8e398dac46f33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c0bd492c2b760e52d18334a76526112 |
| publicationDate | 2021-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021252895-A2 |
| titleOfInvention | Compositions and methods for the treatment and prevention of neurological disorders |
| abstract | The invention provides compositions and methods for treating neurological disorders, such as amyotrophic lateral sclerosis, frontotemporal degeneration, and Alzheimer's disease, among others. Using the compositions and methods described herein, a patient having a neurological disorder, such as a neurological disorder associated with TAR-DNA binding protein (TDP)-43 aggregation, may be administered an inhibitor of FYVE-type zinc finger containing phosphoinositide kinase (PIKfyve) so as to treat an underlying etiology of the disorder and/or to alleviate one or more symptoms of the disease. The inhibitor of PIKfyve may be a small molecule, an anti-PIKfyve antibody or antigen-binding fragment thereof, or a compound, such as an interfering RNA molecule, that attenuates PIKfyve expression. Patients that may be treated using the compositions and methods described herein include those that express are susceptible to developing TDP-43- mediated aggregation and toxicity. |
| priorityDate | 2020-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 762.